BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Adams Laboratories, Inc. Announces Initial Public Offering


10/19/2005 5:13:07 PM

CHESTER, N.J., March 25 /PRNewswire-FirstCall/ -- Adams Laboratories, Inc., a specialty pharmaceutical company, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. A portion of the shares will be issued and sold by Adams Laboratories, and a portion will be sold by certain stockholders of Adams Laboratories.

Merrill Lynch & Co. and Morgan Stanley are acting as joint book-running managers for the offering. In addition, Deutsche Bank Securities and RBC Capital Markets are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

When available, copies of the preliminary prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 (telephone: 212-449-1000) or Morgan Stanley, Prospectus Department, 1585 Broadway, New York, New York 10036 (telephone: 212-761-4000).

About Adams Laboratories, Inc.

Adams Laboratories is a specialty pharmaceutical company headquartered in Chester, New Jersey. Adams Laboratories currently markets two over-the-counter pharmaceuticals for the treatment of respiratory disorders under the Mucinex(R) brand name.

Contact Information: Investor Relations Robert Ferris 212-994-7505 Tom Pratt 212-994-7563 Media Relations Kajal Jhaveri 212-593-5864 847-331-4202

Adams Laboratories, Inc.

CONTACT: Investor Relations, Robert Ferris, +1-212-994-7505; or TomPratt, +1-212-994-7563, or Media Relations, Kajal Jhaveri, +1-212-593-5864, or+1-847-331-4202, all for Adams Laboratories, Inc.



Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES